Efficacy of low-dose intravenous cyclophosphamide in systemic lupus erythematosus presenting with Guillain-Barre syndrome-like acute axonal neuropathies: report of two cases

Lupus. 2013 Mar;22(3):324-7. doi: 10.1177/0961203313476358.

Abstract

There are few cases of Guillain-Barré syndrome (GBS), particularly of atypical variants, occurring in association with systemic lupus erythematous (SLE). Reports addressing a specific therapy thus remain almost anecdotal. It is therefore challenging to determine the treatment that is best suited for this subset of patients, especially if initial conventional therapy for GBS fails. We present two cases of GBS-like acute axonal neuropathies, one with acute motor axonal neuropathy (AMAN), and another with acute motor sensory axonal neuropathy (AMSAN), presenting early in the course of SLE. The first case failed to respond to therapy with intravenous immunoglobulins (IVIG) and plasmapheresis, but achieved a favorable outcome when high-dose glucocorticoids along with low-dose intravenous (IV) cyclophosphamide pulses were given. The second case responded favorably to high-dose glucocorticoids, IVIG, and low-dose IV cyclophosphamide pulses. Both patients have remained in clinical remission and without neurologic sequelae after 10 and three years of follow-up, respectively.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cyclophosphamide / administration & dosage*
  • Female
  • Guillain-Barre Syndrome / diagnosis
  • Guillain-Barre Syndrome / drug therapy*
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Lupus Erythematosus, Systemic / diagnosis
  • Lupus Erythematosus, Systemic / drug therapy*
  • Polyneuropathies / diagnosis
  • Polyneuropathies / drug therapy*
  • Young Adult

Substances

  • Immunosuppressive Agents
  • Cyclophosphamide